

Updates to medical pharmacy prior authorization, post-service claim edits

Security Health Plan requires prior authorization (PA) and post service claim edits (PSCE) on office-administered, medically billed medications to ensure coverage and appropriate payment for those services. The following changes will occur to our medical pharmacy program administered by Prime Therapeutics.

The following will be a benefit exclusion effective July 1, 2026:

- Itvisma

The following will require a prior authorization effective Aug. 1, 2026:

- Yartemlea

The following will require prior authorization and step therapy effective Aug. 1, 2026:

- Exdensur (preference of Cinqair, Fasenra, and Nucala)
- Nufymco (preference of Avastin)
- Boncresa (preference of Jubbonti and Stoboclo)
- Bosaya (preference of Jubbonti and Stoboclo)
- Enoby (preference of Jubbonti and Stoboclo)
- Denosumab-bbdz (preference of Jubbonti and Stoboclo or Wyost and Osenvelt)
- Osvryti (preference of Jubbonti and Stoboclo)
- Aukelso (preference of Wyost and Osenvelt)
- Jubereq (preference of Wyost and Osenvelt)
- Oziltus (preference of Wyost and Osenvelt)
- Xtrenbo (preference of Wyost and Osenvelt)

The following will be an update to the tocilizumab step as of Aug. 1, 2026:

- Avtozma will become a preferred product joining Tyenne.

Going forward, Prime Therapeutics – Security Health Plan’s specialty pharmacy medication partner – will manage prior authorization. Please call (800) 424-8243 or visit their website for details. You can review the full list of all medications requiring a prior authorization or post service claim edit on [Security Health Plan’s website](#). Contact our provider experience team with questions at (800) 548-1224.